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Aptamer-based Field-Effect 
Biosensor for Tenofovir Detection
N. Aliakbarinodehi1, P. Jolly2, N. Bhalla2,†, A. Miodek2,‡, G. De Micheli1, P. Estrela2 & S. Carrara1
During medical treatment it is critical to maintain the circulatory concentration of drugs within their 
therapeutic range. A novel biosensor is presented in this work to address the lack of a reliable point-of-
care drug monitoring system in the market. The biosensor incorporates high selectivity and sensitivity 
by integrating aptamers as the recognition element and field-effect transistors as the signal transducer. 
The drug tenofovir was used as a model small molecule. The biointerface of the sensor is a binary self-
assembled monolayer of specific thiolated aptamer and 6-mercapto-1-hexanol (MCH), whose ratio 
was optimized by electrochemical impedance spectroscopy measurements to enhance the sensitivity 
towards the specific target. Surface plasmon resonance, performed under different buffer conditions, 
shows optimum specific and little non-specific binding in phosphate buffered saline. The dose-response 
behavior of the field-effect biosensor presents a linear range between 1 nM and 100 nM of tenofovir and 
a limit of detection of 1.2 nM. Two non-specific drugs and one non-specific aptamer, tested as stringent 
control candidates, caused negligible responses. The applications were successfully extended to the 
detection of the drug in human serum. As demonstrated by impedance measurements, the aptamer-
based sensors can be used for real-time drug monitoring.
Label-free therapeutic drug monitoring (TDM) by means of electrochemical1 and field-effect biosensors2 has 
gathered significant interest in the last decade since it can lead to personalized point-of-care (POC) therapy appli-
cations3–6. The main advantages of electrochemical and field-effect biosensors over traditional optical techniques 
for TDM are their availability, cost effectiveness, simplicity and portability. Drug biosensors are key elements in 
bringing treatments to the patient’s bedside. They have completely changed and improved the traditional dosing 
regimen to a mechanism that administers the medication based on the patients’ characteristics (genetic profile, 
age, race, gender, environmental agents, etc.) and drug influences, including pharmacodynamics, pharmacoki-
netics, drug-drug interactions, adverse effects, etc7–11. In other words, patients take advantage of point-of-care 
biosensors to control the circulating drug concentration in their body over time themselves, and administer the 
optimum dosage of drugs in need.
For the continuous monitoring of therapeutic compounds, enzymatic biosensors that utilize cytochrome 
P450 (CYP450) as specific bio-probes and amperometric detection have been developed as drug detection sys-
tems thanks to their simplicity and their compliance with point of care TDM requirements12. CYP450-based 
electrochemical sensors present an optimal sensitivity and detection limit that addresses therapeutic ranges for 
many drugs, especially once coupled with multi-walled carbon nanotubes13–15. They enable lower selectivity with 
respect to affinity-based biosensors considering that each CYP450 enzyme can have a wide range of substrates 
or inhibitors. However, the lifetime of such biosensors is still fairly short, thus limiting their application range in 
continuous monitoring12. The need for more robust electrochemical biosensors for continuous drugs monitor-
ing that picks out one specific target is still not yet fully addressed. To overcome the above-mentioned issues, an 
n-channel metal-oxide semiconductor field-effect transistor device (n-MOSFET) with an extended gate function-
alized with a drug-specific DNA aptamer is used in this work. The gate of the transistor is physically connected 
to an external gold electrode, which is used for functionalization with an aptamer specific to a drug and exposed 
to the measurement sample. When the potential applied across the gate and the source (Vgs) is larger than the 
threshold voltage (Vth) of the device (Vgs > Vth), a conducting channel is formed between the source and the 
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drain. Additionally, if a voltage is applied between the drain and source (Vds > 0), then a current (Id) begins to flow 
through the induced channel under the gate dielectric. This condition of the device is known as turn-on state. Any 
changes across Vgs can modulate the conductivity of the channel and alter Id. If molecular interactions take place 
at the gate of the transistor, such as when negatively charged small molecules (for instance drugs) are captured by 
recognition probes (aptamers in this work), the minimum Vgs required to bring the n-MOSFET to the turn-on 
state is increased (gating effect). This is used to quantify the binding event by monitoring the shift of the transfer 
characteristic (Id vs. Vgs curve) of the transistor after the target molecule binding16,17.
Aptamers are short oligonucleotide sequences that can strongly bind to their targets with high affinity and 
specificity thanks to specific conformational changes. Aptamers have several advantages with respect to antibod-
ies. For instance, selection of aptamers is performed through an in vitro process. Once the aptamers are selected, 
they can be further synthesized in a controlled fashion with high purity and reproducibility. Additionally, aptam-
ers are chemically more stable and they retain most of their functionality even after multiple regeneration steps18,19. 
Such a regeneration step is advantageous for continuous monitoring studies. For example, Ferguson et al.4  
have proposed a novel selective and sensitive real-time small molecule monitoring method that uses aptamers as 
recognition elements, and prevents the interaction of blood molecules with the sensing surface by a continuous 
flow diffusion filter in order to suppress sensor fouling. As oligonucleotides can be easily modified with different 
reactive chemical groups, their immobilization on surfaces can be easily controlled. Thanks to such flexibility, 
aptamers are very popular for the design and optimization of novel biosensors20. Such probes, e.g. DNA aptamers, 
are gaining significant attention for the detection of several small molecules21.
As a case study for the development of a biosensor for drug monitoring, the targeted drug tenofovir (TFV) 
was used in the current work. TFV is an antiretroviral drug that was approved by the FDA in 2001 for medi-
cal prevention and treatment of patients with human immunodeficiency virus (HIV) infections and treatments 
for hepatitis-B. Electrochemical biosensors for small molecule sensing have been investigated for the last forty 
years22, yet a reliable system has not been characterized completely, to the best of our knowledge. Therefore, a 
highly selective and sensitive aptamer based biosensor for continuous monitoring of drugs in buffer and plasma 
is proposed in our work (AptaFET). This biosensor is based on the combination of aptamers for target recognition 
and field-effect transistors for the transduction of the drug-probe interaction to an electric signal (schematic and 
more detail in Supplementary Material, Figure S3).
Results
The sensor response to specific and non-specific drug− aptamer interaction was measured by surface plasmon 
resonance (SPR) at different buffer conditions. Electrochemical impedance spectroscopy (EIS) was used to opti-
mize the biosensing interface by finding the best ratio between thiolated aptamer and MCH concentrations used 
on the immobilization process. To obtain the dose-response behavior of the system, the AptaFET biosensor was 
measured upon interaction with different concentrations of TFV in PBS buffer. Control experiments were carried 
out using Abi and Enza (non-specific drugs) and a PSA-aptamer (non-specific aptamer). AptaFET application 
for drug monitoring in human plasma was investigated by detecting 500 nM of TFV in human plasma. Real time 
impedance was used to investigate the performance of the sensing interface under flow conditions enabling the 
application of the biosensor in real time drug monitoring.
Binding reaction investigation. Surface Plasmon Resonance (SPR) experiments were carried out as a 
primary study utilizing two parallel channels simultaneously on each biofunctionalized chip in order to verifiy the 
functionalization of the sensing surface. Binding of targets to the sensing surface was studied using SPR exper-
iment at different buffer conditions, with one channel used for drug spiked sample and the other one for blank 
buffer. The sensing surface was modified with MCH and TFV specific aptamer (TFV-aptamer) as described in 
the bioelectrode development section. TFV and abiraterone (Abi) solutions with concentrations of 500 nM were 
injected and the variations of reflectivity angle were monitored during the incubation cycle. This was followed by 
washing steps to remove all non bonded residues. Abi (a prostate cancer drug) was used as a negative control to 
study the specificity of the detection. Experiments were carried out in phosphate buffer (PB; pH 7.0), phosphate 
buffer saline (PBS; 10 mM; pH 7.4) and PBS containing 1 mM MgCl2 (PBS-MgCl2). A washing step was carried 
out using the same buffer but without the drug. The recorded signals exhibited much lower target binding effect 
for experiments performed in PB and PBS with respect to PBS-MgCl2 (Fig. 1), in which binding reactions were 
clearly observed for both TFV (as target molecule) and Abi. SPR response showed positive binding interaction 
for both experimented drugs. This was observed as an increment of refractive index unit (RIU) in the SPR signal. 
Nevertheless, Abi molecules were removed from the surface during the dissociation cycle, while TFV molecules 
remained bound to the aptamers. After 20 minutes of incubation specific interaction of aptamer/TFV resulted in 
a variation of reflectivity angle of Δ RIU = 15 μ RIU with respect to the non-specific interaction and Δ RIU = 22 μ RIU 
with respect to the blank buffer.
Sensing surface optimization. The sensing surface was optimized by using electrochemical impedance 
spectroscopy (EIS). A schematic diagram of the sensing interface, containing the chemical structure of TFV is 
presented in Fig. 2. Several sensing surfaces were prepared with 1:10, 1:50, 1:100 and 1:150 ratios of thiolated 
aptamer to total thiol molecules (aptamer + MCH), and tested by EIS in the presence of 500 nM of TFV. Upon 
binding of the aptamer to the drug, the aptamer undergoes a conformational change, increasing the charge den-
sity closer to the electrode and hence increasing the electrostatic potential barrier to the negativelly charged redox 
marker – i.e. an increase in Rct is observed. The average of Rct shifts for each aptamer:MCH ratio is presented in 
Fig. 3. It is observed that the optimized ratio in terms of specific response is 1:100, showing 15.0 ± 5.5% of Rct shift 
with respect to the baseline (blank measurement). This value is ~2.4 times higher than 6.3 ± 0.9% of shift corre-
sponding to the 1:50 ratio. Although in this experiment a large deviation was observed in the measured response, 
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Figure 1. Specific interaction of TFV and TFV-aptamer (black line), and non-specific interaction of Abi 
with TFV-aptamer (red line). Blank response is illustrated in blue. A 15 μ RIU difference was recorded between 
specific and non-specific interactions.
Figure 2. Binary SAM of TFV-aptamer and MCH as sensing surface of biosensor. In the inset: chemical 
structure of TFV with red color for Oxygen, purple for phosphorus, light blue for carbon, white for hydrogen 
and dark blue for nitrogen.
Figure 3. Sensing surface optimization. Blue bars indicate EIS responses of AptaFET to 500 nM of TFV 
exploiting various aptamer to MCH ratios. Highest RCT shift for 1:100 ratio. Error bars in this and following 
Figures represent the standard error of triplicate measurements carried out on three electrodes.
www.nature.com/scientificreports/
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the trend of the recorded responses was the same for all samples and following the averaged signal. The optimized 
ratio of 1:100 achieved in this work is consistent with results reported by Formisano et al.23 for a prostate specific 
antigen aptamer (PSA-aptamer):MCH binary layer. This PSA-aptamer had a similar length (32 nucleotides) and 
a two-dimensional structure as the TFV-aptamer used in our work. They have also reported a surface density of 
aptamers equal to 1 × 1012 molecules cm−2 for a similar sensing surface formed on a gold electrode of the same 
size and shape as in this work.
Dose-response behavior. In order to study the sensing performance of the system, the AptaFET biosensor 
was used to detect various concentrations of TFV. The incubation procedure and other experimental details are 
provided in the Apparatus and setup section. In addition, the same experiment was carried out using 500 nM 
of both Abi and enzalutamide (Enza) solutions as negative controls on separate electrodes (without having pre-
ceeding reaction with TFV) to examine the selectivity of the AptaFET for TFV. In order to study the interaction 
of TFV with a non-specific sensing surface, electrodes were functionalized with a binary layer of PSA-aptamer 
and MCH (1:100 ratio) and tested with a 500 nM TFV solution. The dose-response curve of the AptaFET (aver-
aged voltage shift responses versus logarithm of concentrations) is shown in Fig. 4. Controls are also presented 
in the figure for comparison. The curve followed a sigmoidal behavior with a linear range between 1 nM and 
100 nM, and showed saturation after 100 nM. A limit of detection of 1.2 nM was calculated for the biosensor 
following the method described by Armbruster et al.24. Abi, Enza and PSA-aptamer experiments exhibited 
1.3 ± 4.7 mV, 3.3 ± 0.9 mV and 2.7 ± 0.3 mV of Id-Vgs shift, respectively. These are negligible when compared to 
the 22.3 ± 1.8 mV shift obtained for TFV at the same concentration (500 nM).
Detection of TFV in human plasma. The performance of the TFV AptaFET was also assessed using 
human blood plasma. First, the interference of non-specific coexisting proteins of human serum on the biosensor 
was measured. To perform the experiment biofunctionalized electrodes were incubated with blank plasma (after 
stabilizing and taking the baseline in buffer) for half an hour and tested in PBS to obtain the response of plasma 
proteins and biolayer interactions. This interaction caused either small positive or small negative shifts as output, 
depending on the electrode, with an average response of − 1.9 ± 4.6 mV. Then the electrodes were incubated in 
human plasma spiked with 500 nM of TFV for 30 minutes, and measurements performed in plasma. TFV bind-
ing reaction in human plasma produced a response of 16.3 ± 4.8 mV with respect to the baseline in plasma – see 
Fig. 5.
Application of the biosensor in real-time monitoring. Real-time monitoring of the drug was also 
assessed by measuring the specific binding reaction at the sensing surface in flow conditions. Real-time imped-
ance measurements were used to investigate the TFV− aptamer interaction. Cleaned gold electrodes were func-
tionalized with the optimized ratio of aptamer:MCH. The real part (Z’) of the impedance at 10 Hz was then 
monitored in a flow of 10 mM ferro/ferricyanide solution. Once a stable signal was observed, TFV (in 10 mM 
ferro/ferricyanide) was injected to the flow to a final concentration of 400 nM. Z’ started to increase after some 
seconds, and it stabilized at 123 ± 16 Ω after 2 minutes. The same experiment was performed using Abi as a 
non-specific target, which yielded null resistance increment in flow conditions. The results are shown in Fig. 6 
after baseline correction.
Discussion
TFV is classified as a nucleotide analogue reverse transcriptase inhibitor (NRTI). Reverse transcriptase is a crucial 
viral enzyme in retroviruses such as HIV and hepatitis-B virus infections25. Based on the pharmacokinetics data 
reported by Anton et al.26, after oral administration of TFV the circulatory plasma concentration is in the range 
of 20 nM to 860 nM.
In order to achieve good sensitivity and specificity of our TFV aptasensor, an optimization of the sensor sur-
face is fundamental. Changing the ratio of aptamer to MCH in the immobilization solution gives the possibility 
to modify the surface coverage of the aptamer and alter the interaction between the molecules on the surface. A 
Figure 4. Dose-response curve of AptaFET biosensor. Specific response (blue points) fitted to hill function 
with linear range between 1 nM and 100 nM, and EC50 of 5.8 ± 0.5 nM. Responses related to non-specific drugs 
and non-specific aptamers as negative controls in purple green and yellow colour.
www.nature.com/scientificreports/
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balance is required between the amount of aptamers available on the surface and avoiding steric hindrance effects 
due to the conformational changes of the aptamer required for the binding. This helps increase the sensitivity and 
selectivity of the biosensor towards TFV, providing low enough LOD and minimum non-specific interactions. 
The EIS response presented in Fig. 3 shows a signal loss with either high and low aptamer to MCH ratio. This 
suggests that too high a quantity of aptamers immobilised on the surface will prevent the binding and folding due 
to steric hindrance as well as strong electrostatic repulsion between the aptamers. This will reduce the response 
amplitude of the system in terms of Rct variation or lower Id-Vgs characteristic shift for field-effect measurements. 
On the other hand, when there are too few aptamers on the surface, there is low TFV binding and reduction of 
the response. The latter also increases the possibility of non-specific response of the system due to possible inter-
actions of proteins with MCH.
Real-time monitoring impedance experiments (Fig. 6) show the quality of TFV binding to the specific 
aptamer, and minimum non-specific interferences in flow conditions, demonstrating the capability of the biosen-
sor to be exploited in real-time drug monitoring.
As presented in Fig. 5, high selectivity is achieved for the AptaFETs, both in PBS buffer and in blood plasma. 
Negligible non-specific binding responses are observed for controls such as Enza and Abi, and also for the inter-
action of target with non-specific sensing surfaces (anti-PSA aptamer). The data shows a comparable AptaFET 
response for TFV detection in blood plasma to the one obtained in buffer. Exposure of the sensing surface to 
blank human plasma shows high resistance to fouling by plasma proteins, since the response of the biosensor to 
non-specific plasma proteins was negligible compared to the specific response to the drug (orange bar in Fig. 5). 
In addition, there is the possibility of exploiting the same detection system for a wide range of targets just by 
exchanging the TFV-aptamer with an aptamer specific to the new target, thanks to the low non-specific binding 
Figure 5. AptaFET response comparison. Response of biosensor to TFV in PBS (blue), in human plasma 
(black patterned). Non-specific response to negative controls: Enza (red), Abi (green) and blank blood plasma 
(orange). Non-specific response of TFV and PSA-aptamer interaction (purple bar). All target concentrations are 
500 nM.
Figure 6. Real-time monitoring of the real part of the impedance at 10 Hz for an electrode modified with 
TFV aptamer upon injection of TFV as the specific target (blue) and Abi as non-specific target (red). 
Baselines were subtracted for better comparison.
www.nature.com/scientificreports/
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reactions between the biomolecules in the sample and the sensing surface. This has been reported before for other 
types of aptamer-based biosensors4.
The small positive and negative shifts of the FET output as response to plasma interaction was expected, since 
blood plasma contains various ranges of proteins with different charges that can bind to the surface and modulate 
the channel in different and contradictory ways. Moreover, Abi has also presented opposite signal shifts, which 
is due to the nature of its chemical structure; different interactions with the SAM layer causes different channel 
modulation and, thus, opposite signal shift of the output.
The calculated LOD of the AptaFET is 1.2 nM, which is lower than what has been reported with usual elec-
trochemical sensors, for example, on cytochromes P45013. This shows the extremely good performance of this 
novel AptaFET for applications such as a TFV monitoring system. The LOD of the AptaFET falls well within the 
therapeutic range of TFV. In addition, the dose-response curve (Fig. 4) exhibits a highly sensitive linear range 
between 1 nM and 100 nM. The linear range of the AptaFET is lower than the therapeutic range of the target, and 
the system saturates before the maximum of the range (860 nM). This difference is an advantage for drug detec-
tion in human fluids, as it gives the possibility of sample dilution that will decrease the non-specific interactions 
and interferences related to the various metabolites that coexist in human plasma. To compare non-specific and 
specific responses, a high concentration of a non-specific drug was used to show that even at such high concen-
trations the response of the biosensor is negligible. The aptamer used in this work has been characterized by 
Kammer et al.27 using backscattering interferometry with a Kd value of 9 ± 1.4 nM. They presented the specificity 
of the aptamer to its target by using penicillin as a negative control. The response of the AptaFET presented in 
this work is consistent with the data published by Kammer et al. The EC50 = 5.8 ± 0.5 nM, which is calculated 
based on the dose-response curve for the biosensing surface, alongside the Kd value of 9 ± 1.4 nM27 demonstrate 
a high affinity of the aptamer towards TFV and, thus, strong drug-aptamer binding. The possibility of loosing 
bonded drugs without an extensive effort is very low. Nevertheless, we expect a small amount of drug dissoci-
ation and association on the surface that reaches equilibrium and does not produce significant interferences in 
biosensor response. A list of recent publications (after 2013) on small molecule monitoring is summarized in 
Tables 1 and 2. The performance of the AptaFET in terms of LOD and linear range is better or comparable to 
other biosensors that are suitable for POC analytical applications (Table 1), or even the ones utilizing very com-
plex and time consuming sample preparation or complex analytical processes (Table 2). These techniques are less 
suitable or not suitable at all for POC drug monitoring. For instance, fluorescent-based analytical methods need 
laboratory-labeling processes, which are complex and can interfere with the functionality of the biomolecule. 
Some label-free optical and mass spectrometry methods require professionals for operation or their application 
is limited to a specific class of biomolecules (not all the molecules are ionizable). Although low LODs have been 
obtained for some small molecules using different techniques, the LOD of this work is the lowest in the litera-
ture for TFV detection and fully suitable for clinical applications. Comparing the data presented in this work 
with the literature shows the main advantage of our novel AptaFET with respect to many of the reported small 
molecule analytical methods suitable for POC applications. This work compared quite well with other works in 
literature4,21,28,29 in terms of sensitivity and selectivity (see Table 1). It works very well in human plasma with an 
extremely good detection and capability to provide real-time monitoring.
Target Analytical method† LOD Linear range References
Acetaminophen Amperometry and DPV 2.1 nM 5 nM to 800 μ M 36
Adenosine EIS 20 fM 0.05 pM to 17 pM 37
Bisphenol A FET 56 pM 1 to 104 fM 38
Chloramphenicol SWV 5 nM 40 to 1000 nM 39
Cocaine DPV 0.13 nM 0.1 to 10 nM 40
17β -estradiol FET 50 nM 50 nM to 1.6 μ M 28
Etoposide DPV 5.4 nM 20 nM to 2 μ M 41
Etoposide SWV 1.29 μ M 10 to 60 μ M 42
Glucose SWV 4 mM 4 to 20 mM 43
Glucose FET 2 mM 2 to 8 mM 44
Kanamycin SWV 14 pM 10 nM to 2 μ M 45
Naproxen CV 16 μ M Up to 300 μ M 12
Oxytetracycline SWV 0.22 nM 1.1 pM to 110 nM 46
Rifampicin Amperometry 50 nM 2 to 14 μ M 47
Streptomycin SWV 10 nM 50 to 1000 nM 39
Tenofovir FET 1.2 nM 1 nM to 100 nM This work
Tenofovir SWCAdSV 1.3 μ M 1.7 to 17.4 μ M 48
Theophylline CV 50 nM Up to 120 μ M 49
Table 1.  Example of recent published works on small molecule detection exploiting POC-compliant 
detection methods. †CV = Cyclic Voltammetry; SWV = square wave voltammetry; FET = field effect 
transistor; EIS = electrochemical impedance spectroscopy; DPV = differential pulse voltammetry; 
EMAT = electromagnetic acoustic transducer; LSV = linear sweep voltammetry; SWCAdSV = square-wave 
cathodic adsorptive stripping voltammetry.
www.nature.com/scientificreports/
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Dealing with the issue of selectivity of the presented sensor, we have also observed with SPR some non-specific 
binding when fluxing Abi on the sensing surface (Fig. 1). This non-specific interaction was expected, considering 
the chemical structure of Abi and the molecules on the surface. The Abi structure harbours three main features, 
including the aromatic nitrogen-containing heterocycle (pyridine moiety), the hydrophobic steroidal core, and 
the hydroxyl group that together increase the non-specific binding of Abi through hydrophobic forces or hydro-
gen binding to electronegative species that exist in the aptamer structure and on the MCH30–32. However, during 
the dissociation cycle, when the surface was washed with blank buffer, the majority of Abi molecules were washed 
away, while the TFV molecules maintained their uptake. This caused the Abi signal to be 15 μ RIU lower than for 
TFV at the dissociation cycle.
In conclusion, this work proposed and characterized a POC drug monitoring method suitable for detection 
in human plasma and real-time monitoring. The LOD and linear range of the biosensor were fit to the physio-
logical ranges of the target. The sensitivity and selectivity of the biosensor towards the specific target was suc-
cessfully tested. In addition, this method can be used for monitoring of other biomolecules by exchanging the 
TFV-aptamer with another aptamer that is specifically produced for the new target. These prove the capability of 
the proposed detection method to be utilized for continuous monitoring of a wide range of small molecules in 
human plasma.
Materials and Methods
Materials. Thiolated TFV-aptamers (5′ -Aptamer-C6 Thiol-3′ ) were commercially provided by BasePair 
Biotechnologies (Pearland, Houston, USA). Thiolated PSA-aptamer (HS-(CH2)6–5′ TTT TTA ATT AAA GCT 
CGC CAT CAA ATA GCT TT 3′ ), human plasma, MCH, potassium phosphate monobasic solution (KH2PO4), 
potassium phosphate dibasic solution (K2HPO4), potassium sulphate (K2SO4), potassium hexacyanoferrate (III), 
potassium hexacyanoferrate (II) trihydrate, magnesium chloride (MgCl2), DMSO and PBS (10 mM; pH 7.4) were 
all purchased from Sigma-Aldrich (UK). Aptamers were unfolded by heating them at 90 °C for 5 minutes and 
letting them cool down to room temperature. TFV, Abi and Enza powders were purchased from Medchemtronica 
(Stockholm, Sweden) and were dissolved in dimethyl sulfoxide (DMSO) to the concentration of 5 mM. PB 
(0.1 M pH 7.0) was prepared by adding 17 mM of KH2PO4, 33 mM of K2HPO4 and 500 nM of K2SO4 to dis-
tilled water. All other reagents were of analytical grade. All aqueous solutions were prepared using 18.2 MΩ cm 
ultrapure water with a Pyrogard filter (Millipore, Feltham, UK).
Biosensor development. The procedure to find out the best sensing surface in terms of the sensitivity, 
selectivity and level of complexity is explained briefly in the Supplementary information. The focus of the optimi-
zation was on improving the performance of the tenofovir-aptamer interaction to enhance the specificity of the 
response. In addition, stability and reliability of the biosensor was tested using different chemistries for building 
the biorecognition surface. Several different sensing surfaces were tested until finally a binary self-assembled layer 
of TFV-aptamer and MCH was chosen to be fabricated on the interface as sensing surfaces (Figures S4 to S7). 
The aptamer was developed for specific interaction with TFV, while MCH was used as a surface blocking-agent 
and spacer between aptamers (Fig. 2). Gold disk working electrodes (radius 1.0 mm, CH Instruments, Austin, 
TX, USA) were cleaned based on the procedure published by Keighley et al. to provide a properly flat and con-
taminant free surface for biomolecule immobilization33. The gold electrodes were then incubated in a solution of 
tenofovir-aptamer and MCH in PB buffer for 16 hours to form the biosensing surface. This step was followed by 
50 minutes of 1 mM MCH backfilling to complete the surface blockage and lifting any aptamers lying down on the 
surface23. These bioelectrodes were used in EIS experiments for sensing surface optimization. The immobilization 
solution consisted of 1 μ M of aptamer and 10, 50, 100 and 150 μ M of MCH in this experiment to obtain different 
aptamer surface coverage (1:10, 1:50, 1:100 and 1:150 ratios of aptamer:MCH, respectively).
Our innovative AptaFET biosensor consists of a home-designed n-MOSFET structure combined with an 
extended gate (more details in Supplementary material, including the schematic in Figure S3). Detailed informa-
tion on the specifications of the n-MOS chip has been reported elsewhere16. Arrays of gold electrodes (180 nm Au 
Target Analytical method† LOD Linear range References
Acetaminophen UV-Vis spectroscopy 1.8 μ M 6 to 38 μ M 50
Adenosine Fluorescent spectroscopy 3 μ M 1 to 25 μ M 51
Bisphenol A Fluorescent spectroscopy 8 nM 44 to 350 nM 52
Diclophenac Reflectometric interference spectroscopy 0.4 nM 0.4 nM to 3.4 nM 53
Etoposide Fluorescent spectroscopy 850 nM 850 nM to 34 μ M 54
Glucose UV-Vis spectroscopy 10 nM — 55
Kanamycin Fluorescent spectroscopy 0.44 nM 0.5 to 20 nM 56
Naproxen UV and Fluorescent spectroscopy 0.9 nM — 57
Oxytetracycline Cantilever deflection 0.2 nM 10 to 100 nM 58
Tenofovir Mass spectroscopy 0.87 nM 3.5 to 3500 nM 59
Tenofovir‡ FET 1.2 nM 1 nM to 100 nM This work
Table 2.  Example of recent published works on small molecule detection exploiting methods that are not 
compliant to POC drug monitoring. †UV = ultraviolet; Vis = visible; BSI = backscattering interferometry. 
‡This work is inserted here for comparison.
www.nature.com/scientificreports/
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thickness on 20 nm Cr) were deposited on a glass substrate using thermal evaporation. Electrodes were cleaned 
by acetone, ethanol and ultrapure water, sequentially and repeatedly, and then they were functionalized with the 
aptamer as described earlier. The extended gate was fabricated by connecting the biofunctionalized Au electrodes, 
fixed in a reaction cell, to the gate of an n-MOSFET via a metal wire.
Apparatus and setup. Surface plasmon resonance (SPR) measurements were performed using a Reichert 
SPR 7000DC (USA) dual channel flow spectrometer at 25 °C. 50 nm gold coated SPR gold chips, supplied from 
Reichert Technologies were used for studying the reaction on SPR. Prior to their modification, the chips were 
cleaned using piranha solution (3:1 H2SO4:H2O2) for 20 seconds and rinsed thoroughly with MilliQ water and 
dried using nitrogen gas. Modification of the SPR chips with DNA aptamers was performed in the same way 
as described earlier. All buffers were filtered through 0.2 μ m filters and degassed for 2 h by sonication prior to 
the experiment. To perform the experiment, 500 nM solutions of TFV and Abi were flowed over the biofunc-
tionalized chips for 20 minutes with a flow rate of 25 μ L min−1, and followed by 5 minutes of a dissociation step 
to remove all the unbound residues. For the EIS experiments, a μ AUTOLAB III/FRA2 potentiostat (Metrohm, 
Netherlands) and a three-electrode cell setup consisting of biofunctionalized gold working electrode, Ag/AgCl 
reference electrode (via a salt bridge filled with 0.1 M PBS pH 7.4) and platinum counter electrode (ALS, Tokyo, 
Japan) were used. The measurements were carried out in PBS buffer solution containing 10 mM of ferro/ferri-
cyanide [Fe(CN)6]3−/4− redox couple (hexacyanoferrate II/III), applying a 10 mV a.c. voltage superimposed on 
a +0.2 V of d.c. potential (formal potential of the redox couple), in the frequency range of 100 kHz to 0.1 Hz (61 
frequency steps). After a stable signal was observed with blank solutions, the biofunctionalized electrodes were 
incubated in 500 nM solution of TFV for 30 minutes and washed in buffer before the EIS spectra was measured. 
For real time impedance monitoring, a three-electrode flow cell was connected to a CompactStat potentiostat 
(Ivium Technologies, The Netherlands). The impedance was monitored every 0.2 s at a single frequency of 10 Hz 
with a 10 mV amplitude superimposed on a 0.2 V d.c. bias potential. Solutions of TFV and Abi were injected once 
a stable baseline was reached to obtain the total concentration of 400 nM in the flow. To operate the field-effect 
measurements using the AptaFET, a Vds of 50 mV was applied across the drain to source and Vgs was swept from 
0 to 4 V. These settings limited the Id to less than 75 μ A to avoid any false measurement due to device heating 
effects. Biofunctionalized electrodes were stabilized in PBS buffer, and then incubated for 30 minutes in 100 pM, 
1 nM, 2 nM, 5 nM, 10 nM, 30 nM, 100 nM, 500 nM, 1 μ M and 10 μ M solutions of TFV in PBS-MgCl2. They were 
then washed and measured in PBS to obtain the dose-response curve. The AptaFET was further measured with 
500 nM of Abi and Enza as negative controls using the same procedure. Finally, a PSA-aptamer with the length 
(32 nucleotides) and two-dimensional structure similar to the TFV-aptamer was used in order to investigate the 
interaction of TFV with a non-specific sensing surface of the same length and structure. For the experiments on 
plasma samples, drugs were solved in blank human plasma to the final required drug concentrations.
Statistical analysis. All the indicated errors in this work (including the error bars in figures) are the stand-
ard deviation of triplicate measurements performed on three separate electrodes that are produced and experi-
mented under the same conditions. Nonlinear regression was used to fit a modified version of the Hill function 
(equation 1) as an empirical model to the dose response data presented in Fig. 4. This model was prefered to the 
normal Hill function, because it correlates the recorded effect (response of biosensor) to the binding reaction 
(analyte concentration), while the conventional Hill function describes the relation between the binding reaction 
and the concentration of the occupied binding sites34,35. The nonlinear regression analysis was performed using 
the fitting tools of Origin 8.5 (OriginLab, USA).
= +
−
+ ( )
Y E E E
1
(1)
nmin
max min
10
10
LogEC
X
50
To obtain the LOD of the biosensor, first LODΔV was calculated using equation 2 and 324, and then it was con-
verted to concentration using the fitting equation (equation 1).
= ± .LOB mean SD1 645( ) (2)blank blank
= ± .∆ −LOD LOB SD1 645( ) (3)V lowest concentration
where meanblank = 1.8 mV and SDblank = 1.2 mV are the average and standard deviation of 3 blank measurements, 
respectively. SDlowest-concentration = 4.3 mV is the standard deviation of the 3 responses related to the lowest concen-
tration of TFV experimented (100 pM in this work). LOB = 3.8 mV or limit of blank, is the highest blank meas-
urement response obtained by testing 3 blank samples. LODΔV = 10.8 mV is the lowest response caused by TFV 
that is distinguishable from LOB, and can be considered as a reliable detection of the drug. EC50 = 5.8 ± 0.5 nM is 
the calculated concentration that produces half the maximum binding response. The calculations result in a LOD 
of 1.2 nM for the AptaFET, an extremely good performance for an electrochemical sensor. The average reproduc-
ibility measured for the dose-response curve beyond the limit of detection is equal to 36.5%.
Although the dissociation constant (Kd) can be considered to be roughly equal to EC50, it is not possible to 
directly calculate its exact value using the fitting model of this work35.
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